NDA 206099 · Azurity
Onzetra Xsail
Sumatriptan Succinate · Nasal
DiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 20, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jan 27, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
113
33 Phase 3, 5 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ONZETRA XSAIL · SUMATRIPTAN SUCCINATE EQ 11MG BASE · POWDER, NASAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Sumatriptan" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine HeadachesPivotal-lookingCompleted
POZENIndustry
NCT00433732 · 1,400 participants · Start Aug 2004
Drug: sumatriptan; naproxen sodium · For: Migraine Headaches
Sites: Little Rock, Arkansas; Chapel Hill, North Carolina
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00898677 · 1,268 participants · Start Sep 1995 · Primary completion May 1996
Drug: rizatriptan benzoate; rizatriptan benzoate and 2 more · For: Migraine Headache
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane HeadachesPivotal-lookingCompleted
POZENIndustry
NCT00434083 · 1,200 participants · Start Jul 2004
Drug: sumatriptan; naproxen sodium · For: Migraine Headaches
Sites: Chapel Hill, North Carolina; Nashville, Tennessee
- Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and PlaceboPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01986270 · 1,141 participants · Start Dec 1996 · Primary completion Jan 1998
Drug: Placebo; Eletriptan 40 mg and 3 more · For: Migraine With or Without Aura
- Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of MigrainePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01430442 · 1,026 participants · Start Oct 2011 · Primary completion May 2012
Drug: Rimegepant; Placebo and 1 more · For: Migraine; Acute Treatment of Migraine
Sites: Scottsdale, Arizona; Tempe, Arizona; San Francisco, California · 41 sites in all
- Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack StudyPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01986088 · 1,008 participants · Start Nov 1996 · Primary completion Jan 1998
Drug: Placebo; Eletriptan 40 mg and 3 more · For: Migraine With or Without Aura
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00897104 · 933 participants · Start Aug 1995 · Primary completion May 1996
Drug: rizatriptan benzoate (MK0462); Comparator: sumatriptan and 1 more · For: Migraine Headache
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Onzetra Xsail (Sumatriptan Succinate)
2024 spending
$458K
Beneficiaries
119
451 claims
Per beneficiary
$3,846
$57.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $371,408 |
| 2021 | $613,510 |
| 2022 | $576,060 |
| 2023 | $509,065 |
| 2024 | $457,720 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
Robblee J, Minen MT, Friedman BW, et al. · Headache 2026 · Systematic Review, Meta-Analysis
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, et al. · BMJ 2024 · Systematic Review, Comparative Study
- Acute and preventive treatment of menstrual migraine: a meta-analysis.
Khoo CC, Liu CC, Lu M, et al. · J Headache Pain 2024 · Meta-Analysis
- Sumatriptan.
Kaube H, May A, Pfaffenrath V · BMJ 1994 · Clinical Trial, Comment
- Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis.
Zhang H, Qi JZ, Zhang ZH · J Headache Pain 2023 · Systematic Review, Network Meta-Analysis
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, et al. · JAMA Netw Open 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.